CATCH Innovation


Catch innovation invests in promising new therapies, and accelerates their progress by actively supporting young companies to achieve clinical proof of concept with their lead programs. Catch Innovation has a team of professionals who accompany the programs closely and provide hands-on support.




The introduction of new ideas, methods, or invention.


The quality of being honest and of always having high moral principles.


Being responsible for the effects of your actions, and being willing to explain or be criticized for them.

Our Mission

  • To contribute to the enrichment of quality of life around the world through the creation of innovative treatments addressing diverse medical needs.

Our Vision

  • Through strategic investment in people, ideas and partnerships essential to outstanding research in the strategic areas we built innovative products changing Standard of Care.
  • Find the shortest route between Idea and Patient
  • To realize shareholders’ value through highly efficient management



Catch Innovation is a specialist, dedicated to the fight against cancer and viruses. Catch innovation invests in promising new therapies, and accelerates their progress by actively supporting young companies to achieve clinical proof of concept with their lead programs. Catch Innovation has an in-house team of professionals who accompany the programs closely and provide hands-on support.



For life science companies, ultimate success should be measured in effective patient benefit. Catch Innovation works with young companies that employ novel science to develop the most promising and impactful therapies.

Promising therapies will have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed, the improvement in therapeutic benefits as compared to standard of care, and the feasibility of development.

Novel science can innovate in terms of mechanism of action, target, modality, specificity, toxicity,… Above all, novel therapies should be sufficiently differentiated to earn their place among competing therapies in the future standard of care.



Catch Innovation actively participates in the development of the portfolio companies. We aim to support portfolio companies at least up to clinical proof of concept. To this end, Catch Innovation’s development team has experience in translational development, oncology, virology and entrepreneurship. Catch Innovation’s team can assist where useful on preclinical, clinical & CMC development, on IP & regulatory affairs, on licensing, finance & transactions and on general company building. Catch Innovation’s network of leaders gives us access to top-level institutions and KOL’s around the world and allows our portfolio companies to benefit from a global knowledge base.

Our projects

Applied Bioanalytics


Applied Bioanalytics is a bioprocess analytical service provider; a laboratory specialized in high quality bioanalytical support of biologics and biosimilar development pipelines as well as in providing analytical services for the food and beverage industry.

Services offered for the pharma and biopharma industry

  • High resolution glycan profiling
  • Automated carbohydrate sequencing
  • Purity and heterogeneity measurements
  • Charge variant analysis
  • Charge heterogeneity

Measurements for the food and beverage industry to

  • Sugar Component analysis
  • Varietal identification
  • Additives analysis
  • Residue analysis including pesticides and antibiotics

For more information please visit

Pret Therapy


The Nobel-prize awarded checkpoint inhibitors that manipulate the immune system started a Cancer Immunotherapy Revolution. This resulted in regression of cancer in a minority of patients, while the majority suffered severe immune-related adverse events (irAEs) due to tolerance breakdown. Exploiting the well-known antibody-based pretargeting technology we invented a method that anchor autoimmune T cells to tumors such that healthy organs are spared. The pretargeting technology could easily be developed into an off-the-shelve product

Biosystems Immunolab


Lung cancer (LC), Breast cancer (BC), Colon Cancer (CC) are the 3 most prevalent cancer types with the highest death rates. While diagnostic imaging (e.g. CT) and tissue diagnostics (e.g. biopsies) are the most frequently used methods for diagnosing cancer, growing cancer incidence rates are calling for less invasive and cheaper methods of screening the global population. At the same time early detection through frequent screening could improve patient outcomes and save lives. Bio-systems International (BSI) has developed an early stage detection In-Vitro Diagnostic (IVD) for lung cancer, what is patented, registered and ready to be launched. Further application areas for diabetes for the young (MODY), BC and CC are in the pipeline.

Superinfection Therapy

superinfHepC Therapeutics Inc. (Superinfection) is focused on unmet medical needs such as treatment of decompensated hepatitis patients waiting for liver transplants and adjuvant treatment of hepatitis in hepatocellular cancer patients with fragile liver function. HepC – Superinfection’s revolutionary, clinically tested viral superinfection technological platform is based on the non-pathogenic attenuated double stranded RNA (dsRNA) infectious bursal disease virus (IBDV), a master activator of antiviral gene responses. Viral superinfection can also be leveraged for the postexposure treatment of serious viral infections.

Captec Medical


Cancer is the 2nd leading cause of death globally, and was responsible for 8.8 Mio. deaths in 2015. More than 90% of the deaths by cancer are due to metastases. The existing treatment methods for metastases, such as chemotherapy or radiation therapy have serious side effects. They demolish the immune system, take long (6 months to several years) and are expensive. CAPTEC Medical, developed a treatment method that reduces the number of circulating tumor cells (CTCs) in patients’ blood, hence the cells with potential metastatic capability. That method is working with standard dialysis technique. CAPTEC ́s newly developed cartridge, utilizes the antigen – antibody binding concept, activates the membranes of a standard dialysis cartridge to become capable to capture specific cancer cells out of the blood when flowing through it. Parallel removal of CTCs and their metabolites will further alleviate the metastatic process and improve the patients’ quality of life and prolong life expectancy, avoiding 960.000 cancer related deaths or delay them in Europe each year.

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.